GlassScriptPhysician profile
Henghe Tian
NPI 1780875930
$79,526.69
in general payments reported to CMS, 2019-2025
33 companies · $4,152 in 2025
The $4,152 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $8,565 · 2021: $4,399 · 2022: $21K · 2023: $14K · 2024: $5,276 · 2025: $4,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $9,857 · Consulting Fee: $2,160 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,375.00 |
| Food and Beverage | $9,856.83 |
| Consulting Fee | $2,160.00 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53,683.25 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $12,063.65 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Janssen Biotech, INC. | $3,041.91 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $1,771.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,437.82 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,299.22 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,249.55 | 2019-2025 | Taltz |
| Glaxosmithkline, LLC. | $899.40 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $856.36 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $451.00 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $293.56 | 2022-2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $271.10 | 2019-2025 | Orencia |
| Regeneron Healthcare Solutions, INC. | $238.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.93 | 2023-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $227.38 | 2021-2025 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $187.29 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $161.83 | 2019-2024 | Actemra |
| Genzyme Corporation | $130.04 | 2020-2025 | |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Radius Health, INC. | $122.52 | 2019-2023 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $121.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $90.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $86.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $75.01 | 2022-2025 | Strensiq |
| Organon LLC | $42.71 | 2024-2025 | Hadlima |
| Depuy Synthes Sales INC. | $23.89 | 2022 | |
| Fresenius Kabi USA, LLC | $23.50 | 2023 | Idacio |
| Ultragenyx Pharmaceutical INC. | $21.59 | 2021 | |
| Sandoz INC. | $18.28 | 2024 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $16.21 | 2025 | |
| Medexus Pharma, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henghe Tian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.